Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir response-guided therapy in HIV/HCV genotype 1 coinfected prior non-responders
2012-003984-23Phase 3Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Feb 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of boceprevir in chronic hepatitis C virus infection and human immunodeficiency virus infection (HIV), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Sustained virological response at follow-up week 24. Started Feb 2013; status: completed.
02
Drugs
boceprevir
03
Conditions
chronic hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2012-003984-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003984-23.